Elevance's Medicaid Turn Is Real — the Clean Beat Is Not
A $29 guide and a $26.75 base mark the managed-care giant's first credible trough call, but rates still trail cost trend and the EPS beat leans on non-operating items.
ELV · Earnings Call · 2026-10-21
A better quarter, but not a clean beat
Elevance Health came into its 2026-10-21 report as a show-me managed-care story. The stock is up about 8% over the last 90 trading days but still sits roughly 23% below its September 2024 peak. The Q3 print gave the bulls something real: adjusted EPS of $6.99, a raised 2026 guide of at least $29, a higher 2026 baseline of at least $26.75, and management's first unqualified claim that Medicaid is getting better. But the headline guide raise is not all operating. “Third quarter adjusted diluted earnings per share of $6.99 exceeded our outlook.” — Mark Kaye, Chief Financial Officer (CFO) · 2026-10-21 Mark Kaye then separated the pieces: roughly $0.50 of operating outperformance and a $1.85 net non-operating benefit, mostly investment-income valuation and tax items. That matters because the baseline — the number off which the 2027 12% growth promise is measured — rose only $0.75.The GAAP picture is less flattering. In the latest filed quarter, operating margin was 3.8%, down 1.0 point year over year, operating income fell 20%, and effective SG&A rose 21% to $3.2 billion. The Q3 call's adjusted operating expense ratio rose 90 basis points to 11.3% as the company made targeted one-time investments. This is not a companywide margin recovery yet; it is a company buying its way into one.
Medicaid: the language changed
The most important shift was narrative. For several quarters, Medicaid was the problem child: elevated acuity, rate updates lagging trend, and a 2026 margin guide of roughly -1.75%. On the Q2 call, Mark Kaye was explicit that “we are not assuming a material improvement in Medicaid trend in the back half of the year.” — Mark Kaye, CFO · 2026-07-15 On the Q1 call he had defended “continuing to be very comfortable with our guide of minus 1.75% operating margin.” — Mark Kaye, Chief Financial Officer (CFO) · 2026-04-22 Q3 changed the tone: “Medicaid is moving from stabilization to improvement.” — Gail Boudreaux, President and CEO · 2026-10-21 Gail Boudreaux also pointed to rate actions and margin improvement as the reason the full-year Medicaid margin is now slightly ahead of prior guidance. The Q3 MLR of 90.6% was favorable to expectations, with Medicaid, Medicare Advantage, and ACA all contributing.But the caveat is the same one that has dogged the stock. Kaye said rates have not fully caught up with cost.
That is the tension in the whole report. The direction of better rate alignment is real, but the level is still short. Management still views 2%-4% as the right long-term margin target for Medicaid, and the pace of recovery depends on state rate cycles, not just Elevance's cost actions. Work requirements and H.R.1 implementation add an acuity wildcard. Felicia Norwood said states are still developing verification plans, and Elevance is planning for incremental acuity pressure. The company is also leaning on specific cost levers — ABA therapy oversight, behavioral-health utilization review, payment integrity, and network actions — which is a more granular story than the old wait-for-rates story. The old Q4 2025 keyword stack was dominated by program changes, elevated acuity, and rate updates; this quarter those have been pushed down by rate actions and margin improvement.Rates have certainly not fully caught up with the underlying costs, and our focus here is really on closing that gap and then executing against our targeted medical cost actions.
Commercial: pricing discipline versus IDR
Commercial is the quieter part of the call but important for 2027. Elevance says it priced 2026 and 2027 for a low double-digit cost trend, with the independent dispute resolution process baked in. “We priced 2026 and 2027 for a low double-digit cost trend environment.” — Mark Kaye, Chief Financial Officer (CFO) · 2026-10-21 The pressure is concentrated in ASO rather than fully insured, and management is using BlueCard data to challenge claims and price ahead of trend. That is credible, but IDR remains an industry-wide affordability issue. Boudreaux called the process one that is “not consistently achieving the purpose” — Gail Boudreaux, President and CEO · 2026-10-21, citing excessive awards and administrative burden. Elevance supports the consumer protections but wants stronger eligibility controls. For investors, that is a cost trend risk that cannot be fully priced away.The 2027 selling season is better than the macro worry would suggest. Morgan Kendrick said the pipeline started with over 1 million members, several jumbo employers returned to Anthem, and the Second Blue Bid is part of the opportunity set. The Anthem Balance funded product is also getting traction, especially down-market. That is a genuine commercial positive: employers want affordability and simplicity, and Elevance is selling both funded and self-funded structures. Still, the company is not immune to the shift from risk to ASO, which carries different margins.
ACA was the other upside surprise. Elevance ended Q3 with about 1.3 million individual ACA members versus an expectation of 1.2 million, and now expects at least 1.2 million at year-end. The bronze plan mix helped affordability and retention, but it also complicates risk adjustment. Kaye said the risk pool will take more than one renewal cycle to normalize after enhanced subsidies expired. The company has accrued for the Wakely data and feels good about 2027 rates, but this is still a market where favorable claims experience can reverse.
Carelon and the capital question
Carelon remains the growth kicker. CarelonRx operating gain rose 10.8% and margin was 5.3%, helped by specialty dispensing and integrated medical-pharmacy execution. Management says integrated members save up to $100 per member per month and have 30% fewer ER visits. The appointment of Jeff Park as President of Carelon is a signal that Elevance wants to scale external services, not just use Carelon as an internal cost tool. That fits the pharmacy management and care management narrative.Capital deployment, however, stays conservative. Kaye described a “disciplined” — Mark Kaye, Chief Financial Officer (CFO) · 2026-10-21 posture, prioritizing balance-sheet strength and targeted investments, with buybacks opportunistic. That is consistent with the Q2 message and with the fundamentals: interest coverage of 5.3x is down 25% year over year, and repurchases were just $234 million in the latest filed quarter. The raised baseline gives Elevance more flexibility, but not enough to ignore the leverage and margin trajectory.